Cardiology update 2017

• Main Authors: Sunil Kumar Verma, Harish Gupta, Abhishek Gupta
• Format: Article
• Language: English
• Published: Wolters Kluwer Medknow Publications 2016-01-01
• Series: Journal of the Practice of Cardiovascular Sciences
• Subjects: Acute coronary syndrome; congenital heart disease; heart failure
• Online Access: http://www.j-pcs.org/article.asp?issn=2395-5414;year=2016;volume=2;issue=3;spage=142;epage=145;aulast=Verma

In the latter half of 2016, the Danish study evaluated the need of automatic implantable cardioverter-defibrillator in nonischemic cardiomyopathies group of heart failure population. HOPE-3 in 2016 expanded the dimension of statin use. Novel age, biomarker, and clinical history stroke risk score for atrial fibrillation was validated. Success of Phase 2b clinical trial for CSL112 was one more step to reduce the ischemic events in the postmyocardial infarction period. On the one hand, NORSTENT study compared the bare-metal stents with drug-eluting stent, and on the other hand, 3-year follow-up data of ABSORB II trail discussed the performance of bioresorbable scaffolds. NOBLE and EXCEL trials evaluated the coronary intervention with coronary artery bypass graft in the left main coronary artery disease. Reduction of major adverse cardiac event with low-density lipoprotein cholesterol <50 mg/dl was analyzed with alirocumab. Fractional flow reserve was tested as a tool to decide treatment modality in patients with stable coronary artery disease. Natural history of rheumatic heart disease in the current era was described in REMEDY study. A few technological advancements in cardiac resynchronization therapy defibrillator technology were also approved by the Food and Drug Administration. Birth prevalence and pattern of congenital heart disease in North India were presented.